These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 10924113

  • 1. Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase.
    Liu H, Talmud PJ, Lins L, Brasseur R, Olivecrona G, Peelman F, Vandekerckhove J, Rosseneu M, Labeur C.
    Biochemistry; 2000 Aug 08; 39(31):9201-12. PubMed ID: 10924113
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr.
    Liu H, Labeur C, Xu CF, Ferrell R, Lins L, Brasseur R, Rosseneu M, Weiss KM, Humphries SE, Talmud PJ.
    J Lipid Res; 2000 Nov 08; 41(11):1760-71. PubMed ID: 11060345
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein C-II39-62 activates lipoprotein lipase by direct lipid-independent binding.
    MacPhee CE, Hatters DM, Sawyer WH, Howlett GJ.
    Biochemistry; 2000 Mar 28; 39(12):3433-40. PubMed ID: 10727238
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein: effect of apolipoprotein C-II on the catalytic mechanism.
    Shirai K, Fitzharris TJ, Shinomiya M, Muntz HG, Harmony JA, Jackson RL, Quinn DM.
    J Lipid Res; 1983 Jun 28; 24(6):721-30. PubMed ID: 6688442
    [Abstract] [Full Text] [Related]

  • 7. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.
    Larsson M, Vorrsjö E, Talmud P, Lookene A, Olivecrona G.
    J Biol Chem; 2013 Nov 22; 288(47):33997-34008. PubMed ID: 24121499
    [Abstract] [Full Text] [Related]

  • 8. Structure-guided protein engineering modulates helix bundle exchangeable apolipoprotein properties.
    Kiss RS, Weers PM, Narayanaswami V, Cohen J, Kay CM, Ryan RO.
    J Biol Chem; 2003 Jun 13; 278(24):21952-9. PubMed ID: 12684504
    [Abstract] [Full Text] [Related]

  • 9. Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase.
    Shen Y, Lookene A, Nilsson S, Olivecrona G.
    J Biol Chem; 2002 Feb 08; 277(6):4334-42. PubMed ID: 11719505
    [Abstract] [Full Text] [Related]

  • 10. Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli.
    Wang CS, Downs D, Dashti A, Jackson KW.
    Biochim Biophys Acta; 1996 Aug 16; 1302(3):224-30. PubMed ID: 8765143
    [Abstract] [Full Text] [Related]

  • 11. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.
    Meyers NL, Larsson M, Vorrsjö E, Olivecrona G, Small DM.
    J Lipid Res; 2017 May 16; 58(5):840-852. PubMed ID: 28159869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
    Breyer ED, Le NA, Li X, Martinson D, Brown WV.
    J Lipid Res; 1999 Oct 16; 40(10):1875-82. PubMed ID: 10508207
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.
    McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS.
    J Lipid Res; 1992 Jul 16; 33(7):995-1003. PubMed ID: 1431591
    [Abstract] [Full Text] [Related]

  • 15. Guinea pig apolipoprotein C-II: expression in E. coli, functional studies of recombinant wild-type and mutated variants, and distribution on plasma lipoproteins.
    Andersson Y, Lookene A, Shen Y, Nilsson S, Thelander L, Olivecrona G.
    J Lipid Res; 1997 Oct 16; 38(10):2111-24. PubMed ID: 9374133
    [Abstract] [Full Text] [Related]

  • 16. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
    Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC.
    J Lipid Res; 2005 Feb 16; 46(2):297-306. PubMed ID: 15576844
    [Abstract] [Full Text] [Related]

  • 17. An N-terminal three-helix fragment of the exchangeable insect apolipoprotein apolipophorin III conserves the lipid binding properties of wild-type protein.
    Dettloff M, Weers PM, Niere M, Kay CM, Ryan RO, Wiesner A.
    Biochemistry; 2001 Mar 13; 40(10):3150-7. PubMed ID: 11258930
    [Abstract] [Full Text] [Related]

  • 18. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C.
    van Barlingen HH, de Jong H, Erkelens DW, de Bruin TW.
    J Lipid Res; 1996 Apr 13; 37(4):754-63. PubMed ID: 8732775
    [Abstract] [Full Text] [Related]

  • 19. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins.
    Swaney JB, Weisgraber KH.
    J Lipid Res; 1994 Jan 13; 35(1):134-42. PubMed ID: 8138714
    [Abstract] [Full Text] [Related]

  • 20. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
    Wang CS, McConathy WJ, Kloer HU, Alaupovic P.
    J Clin Invest; 1985 Feb 13; 75(2):384-90. PubMed ID: 3973011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.